Literature DB >> 2819920

Human pharmacology of 1S and 1R enantiomers of delta-3-tetrahydrocannabinol.

L E Hollister, H K Gillespie, R Mechoulam, M Srebnik.   

Abstract

Two enantiomers (1S and 1R) of delta-3-tetrahydrocannabinol were assayed in man for psychoactivity. The 1S enantiomer had definite psychic actions, qualitatively similar to those of delta-1-tetrahydrocannabinol, but quantitatively less potent (1:3 to 1:6). Adding the two enantiomers together did not increase the effect, confirming that activity was solely in the one enantiomer and that there was no interaction between them.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2819920     DOI: 10.1007/BF00176485

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  6 in total

1.  The effects of delta1-tetrahydrocannabinol and other cannabinoids on spin-labeled liposomes and their relationship to mechanisms of general anesthesia.

Authors:  D K Lawrence; E W Gill
Journal:  Mol Pharmacol       Date:  1975-09       Impact factor: 4.436

2.  Dimensions of marihuana experience.

Authors:  L E Hollister; J E Overall
Journal:  Drug Alcohol Depend       Date:  1975-12       Impact factor: 4.492

3.  Tetrahydrocannabinol isomers and homologues: contrasted effects of smoking.

Authors:  L E Hollister
Journal:  Nature       Date:  1970-08-29       Impact factor: 49.962

4.  Stereochemical requirements for cannabinoid activity.

Authors:  R Mechoulam; N Lander; T H Varkony; I Kimmel; O Becker; Z Ben-Zvi; H Edery; G Porath
Journal:  J Med Chem       Date:  1980-10       Impact factor: 7.446

5.  Effects of the cannabinoids on physical properties of brain membranes and phospholipid vesicles: fluorescence studies.

Authors:  C J Hillard; R A Harris; A S Bloom
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

6.  Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.

Authors:  A Ohlsson; J E Lindgren; A Wahlen; S Agurell; L E Hollister; H K Gillespie
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.